Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia

Click to increase image sizeClick to decrease image size

Disclosure statement

FH has no disclosures. HK has received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer, and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision Biosciences, Taiho Pharmaceutical Canada. GCI has received research funding from Celgene, Kura Oncology, Syndax, and Novartis, and consultancy fees from Novartis and Kura Oncology. EJ has received research grants from Abbvie, adaptive biotechnologies, Amgen, Pfizer, and Takeda and consultancy fees from Abbvie, adaptive biotechnologies, Amgen, BMS, Genentech, Incyte, Novartis, Pfizer, and Takeda. KS has received research funding and consultancy fees from Novartis, and has membership on Daiichi-Sankyo and Pfizer’s Board of Directors or advisory committees.

Additional information

Funding

This study is supported in part of the MD Anderson Cancer Center Leukemia SPORE CA100632, the Cancer Center Support Grant (CCSG) P30CA016672, and the Charif Souki Cancer Research Grant.